Market Place
Sourcing Support
Novartis` atrasentan shows to reduce proteinuria in Phase III IgAN trial
27 May 2024 //
CLINICALTRIALSARENA
Novartis Atrasentan IgAN Phase 3: Proteinuria Reduction Portfolio Advancement
25 May 2024 //
GLOBENEWSWIRE
Novartis drug candidate scores interim win in rare kidney disease trial
31 Oct 2023 //
REUTERS
Chinook Therapeutics Obtains Worldwide Rights from AbbVie
10 Jan 2020 //
BUSINESS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.